Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01000259 · ClinicalTrials.gov registry record
Study of Tumor Tissue Samples From Patients Who Have Undergone Surgery for Advanced Stage III or Stage IV Ovarian Epithelial Cancer
A clinical trial of Stage IV Ovarian Cancer and Stage IIIA Ovarian Cancer, sponsored by Gynecologic Oncology Group.
- Recruiting
- Registry status
- 174
- Enrollment target
- 1
- Study location
NCT01000259: Recruiting study of Stage IV Ovarian Cancer and Stage IIIA Ovarian Cancer, sponsored by Gynecologic Oncology Group.
NCT01000259 is a study of Stage IV Ovarian Cancer and Stage IIIA Ovarian Cancer that is actively recruiting participants, run by Gynecologic Oncology Group. The registered enrollment target is 174 participants, above the 63-participant average among 5 other Stage IV Ovarian Cancer trials with a reported enrollment target (176% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01000259, a study of Stage IV Ovarian Cancer and Stage IIIA Ovarian Cancer, is actively recruiting participants, sponsored by Gynecologic Oncology Group.
- RECRUITING
- Registry status
- 174 participants
- Enrollment target
- 1
- Study location
Study Summary
This research study is looking at tumor tissue samples from patients who have undergone surgery for advanced stage III or stage IV ovarian epithelial cancer. Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors learn how tumor infiltrating T cells can predict how patients will respond to treatment.
Primary Outcome
The Kaplan-Meier method will be used to estimate the survival curves, and the log-rank test will be used to test the difference between survival curves for TIL positive and negative patients. All of the tests will be two-sided and the significant levels will be set a 0.05.
Conditions Studied
Interventions
- OTHER Laboratory Biomarker Analysis
Study Locations (1)
Pennsylvania
- Gynecologic Oncology Group - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 174 participants |
| Start Date | 2004-09 |
What NCT01000259 shows while recruiting
NCT01000259 is an observational study that tracks outcomes without assigning an intervention. The registered 174 participants enrollment target is mid-sized for trials with a published cap, above the 63-participant average among 5 other Stage IV Ovarian Cancer trials with a reported enrollment target (176% higher).
The record links to 4 conditions, with Stage IV Ovarian Cancer appearing as the primary indexed condition, and to 1 intervention - of which Laboratory Biomarker Analysis is the first listed.
NCT01000259 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT01000259 about?
NCT01000259 is a clinical study titled "Study of Tumor Tissue Samples From Patients Who Have Undergone Surgery for Advanced Stage III or Stage IV Ovarian Epithelial Cancer". This research study is looking at tumor tissue samples from patients who have undergone surgery for advanced stage III or stage IV ovarian epithelial cancer. Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors learn how tumor infiltrating T cells can predict...
What is the current status of trial NCT01000259?
This trial is currently recruiting. The enrollment target is 174 participants. The study started on 2004-09.
What conditions does trial NCT01000259 study?
This clinical trial studies the following conditions: Stage IV Ovarian Cancer, Stage IIIA Ovarian Cancer, Stage IIIB Ovarian Cancer, Stage IIIC Ovarian Cancer.
What interventions are being tested in trial NCT01000259?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER).
Who is sponsoring clinical trial NCT01000259?
This trial is sponsored by Gynecologic Oncology Group, which has 154 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01000259 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Stage IV Ovarian Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Heated Intraperitoneal Chemotherapy Followed by Niraparib for Ovarian, Primary Peritoneal and Fallopian Tube Cancer
RECRUITING · Phase 3
-
A Study Comparing Perioperative Stress Reduction vs. Standard of Care in Ovarian Cancer (PRESERVE)
RECRUITING · NA
-
HOT: HIPEC in Ovarian Cancer as Initial Treatment
ACTIVE NOT RECRUITING · Phase 2
-
Prehabilitation Care for Women With Advanced Ovarian Cancer Receiving Neoadjuvant Chemotherapy
ACTIVE NOT RECRUITING · NA
-
Salvage Ovarian FANG™ Vaccine + Bevacizumab
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04729114 · 174 participants · Phase 1
A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer
- NCT04884035 · 174 participants · Phase 1
Study of Safety and Efficacy of Iberdomide (CC-220) and CC-99282 Combined With R-CHOP to Treat Lymphoma
- NCT05075980 · 174 participants · Phase 2
Intensity Modulated Proton or X-Ray Therapy After Surgery for Treatment of Head and Neck Cancer, the HEADLIGHT Study
- NCT05846685 · 174 participants
Patient Perspectives of an Automated Falls-Risk Screening and Referral Tool in the Emergency Department (ED)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia